AU2013229995B2 - Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor - Google Patents

Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor Download PDF

Info

Publication number
AU2013229995B2
AU2013229995B2 AU2013229995A AU2013229995A AU2013229995B2 AU 2013229995 B2 AU2013229995 B2 AU 2013229995B2 AU 2013229995 A AU2013229995 A AU 2013229995A AU 2013229995 A AU2013229995 A AU 2013229995A AU 2013229995 B2 AU2013229995 B2 AU 2013229995B2
Authority
AU
Australia
Prior art keywords
alk
degrees
salt
compound
fak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013229995A
Other languages
English (en)
Other versions
AU2013229995A1 (en
Inventor
Shawn P. Allwein
Laurent Courvoisier
Martin J. Jacobs
Gregory R. Ott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47892060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013229995(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of AU2013229995A1 publication Critical patent/AU2013229995A1/en
Application granted granted Critical
Publication of AU2013229995B2 publication Critical patent/AU2013229995B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
AU2013229995A 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor Active AU2013229995B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261607305P 2012-03-06 2012-03-06
US61/607,305 2012-03-06
PCT/US2013/029304 WO2013134353A1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor

Publications (2)

Publication Number Publication Date
AU2013229995A1 AU2013229995A1 (en) 2014-09-25
AU2013229995B2 true AU2013229995B2 (en) 2017-04-13

Family

ID=47892060

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013229995A Active AU2013229995B2 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor

Country Status (28)

Country Link
US (5) US9132128B2 (enExample)
EP (2) EP2822939B1 (enExample)
JP (2) JP6016953B2 (enExample)
KR (1) KR102068374B1 (enExample)
CN (2) CN104159894B (enExample)
AU (1) AU2013229995B2 (enExample)
CA (1) CA2865420C (enExample)
CL (1) CL2014002353A1 (enExample)
CY (1) CY1117565T1 (enExample)
DK (1) DK2822939T3 (enExample)
EA (2) EA033124B1 (enExample)
ES (2) ES2681487T3 (enExample)
HR (1) HRP20160387T1 (enExample)
HU (1) HUE027976T2 (enExample)
IL (2) IL234239A (enExample)
ME (1) ME02460B (enExample)
MX (2) MX347772B (enExample)
MY (1) MY177290A (enExample)
NZ (1) NZ630251A (enExample)
PH (1) PH12014501979A1 (enExample)
PL (1) PL2822939T3 (enExample)
RS (1) RS54689B1 (enExample)
SG (2) SG11201405371PA (enExample)
SI (1) SI2822939T1 (enExample)
SM (1) SMT201600134B (enExample)
UA (1) UA115052C2 (enExample)
WO (1) WO2013134353A1 (enExample)
ZA (1) ZA201406147B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102068374B1 (ko) * 2012-03-06 2020-01-20 세파론, 인코포레이티드 이중 alk 및 fak 억제제로서의 융합된 비시클릭 2,4-디아미노피리미딘 유도체
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
CA2971415A1 (en) 2014-12-23 2016-06-30 Shawn P. Allwein Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives
MX2021001398A (es) 2018-08-07 2021-08-16 In3Bio Ltd Métodos y composiciones para la inhibición de la vía egf/egfr en combinación con inhibidores de la cinasa del linfoma anaplásico.
WO2024178339A2 (en) * 2023-02-23 2024-08-29 The Regents Of The University Of Michigan Methods for treating neuroblastoma with a dual anaplastic lymphoma kinase and focal adhesion kinase inhibitor
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080393A1 (en) * 2004-02-14 2005-09-01 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008051547A1 (en) * 2006-10-23 2008-05-02 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
ATE542801T1 (de) 2003-08-15 2012-02-15 Novartis Ag Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
CA2559866A1 (en) 2004-03-31 2005-10-20 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
WO2007098507A2 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EA019941B1 (ru) * 2006-12-08 2014-07-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
DK2146779T3 (en) * 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
ES2668775T3 (es) * 2009-06-10 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Compuestos tetracíclicos
KR102068374B1 (ko) * 2012-03-06 2020-01-20 세파론, 인코포레이티드 이중 alk 및 fak 억제제로서의 융합된 비시클릭 2,4-디아미노피리미딘 유도체
KR101446742B1 (ko) * 2012-08-10 2014-10-01 한국화학연구원 Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CA2971415A1 (en) * 2014-12-23 2016-06-30 Shawn P. Allwein Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080393A1 (en) * 2004-02-14 2005-09-01 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008051547A1 (en) * 2006-10-23 2008-05-02 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors

Also Published As

Publication number Publication date
CA2865420A1 (en) 2013-09-12
EP2822939A1 (en) 2015-01-14
JP2015509540A (ja) 2015-03-30
RS54689B1 (sr) 2016-08-31
IL252364B (en) 2018-03-29
CL2014002353A1 (es) 2015-01-09
NZ630251A (en) 2016-02-26
ES2681487T3 (es) 2018-09-13
EP3056494A1 (en) 2016-08-17
CA2865420C (en) 2020-06-02
ZA201406147B (en) 2015-12-23
HK1226300A1 (zh) 2017-09-29
ES2570976T3 (es) 2016-05-23
US9339502B2 (en) 2016-05-17
EA201691574A1 (ru) 2017-03-31
SMT201600134B (it) 2016-07-01
SG10201507865QA (en) 2015-10-29
PH12014501979B1 (en) 2014-11-24
EA033124B1 (ru) 2019-08-30
JP2017039741A (ja) 2017-02-23
WO2013134353A8 (en) 2014-06-19
WO2013134353A1 (en) 2013-09-12
CN104159894B (zh) 2016-09-07
EA025859B1 (ru) 2017-02-28
MY177290A (en) 2020-09-10
SG11201405371PA (en) 2014-09-26
US20150011561A1 (en) 2015-01-08
HUE027976T2 (en) 2016-11-28
US9132128B2 (en) 2015-09-15
ME02460B (me) 2017-02-20
EP3056494B1 (en) 2018-05-02
EA201491641A1 (ru) 2015-04-30
US20160243119A1 (en) 2016-08-25
US20170173017A1 (en) 2017-06-22
PH12014501979A1 (en) 2014-11-24
US20190328735A1 (en) 2019-10-31
EP2822939B1 (en) 2016-02-17
CY1117565T1 (el) 2017-04-26
CN104159894A (zh) 2014-11-19
UA115052C2 (uk) 2017-09-11
US10632119B2 (en) 2020-04-28
KR102068374B1 (ko) 2020-01-20
IL252364A0 (en) 2017-07-31
DK2822939T3 (en) 2016-03-14
MX347772B (es) 2017-05-12
PL2822939T3 (pl) 2016-08-31
MX2014010613A (es) 2014-09-18
HRP20160387T1 (hr) 2016-05-20
IL234239A (en) 2017-06-29
CN106166155A (zh) 2016-11-30
JP6016953B2 (ja) 2016-10-26
AU2013229995A1 (en) 2014-09-25
HK1205119A1 (zh) 2015-12-11
US9623026B2 (en) 2017-04-18
US20150374693A1 (en) 2015-12-31
KR20140138247A (ko) 2014-12-03
SI2822939T1 (sl) 2016-04-29
MX372740B (es) 2020-05-04
CN106166155B (zh) 2019-01-18
US10111872B2 (en) 2018-10-30

Similar Documents

Publication Publication Date Title
US10632119B2 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
RU2686323C2 (ru) Новые соединения и композиции для ингибирования fasn
KR102136017B1 (ko) 만성 기침의 치료를 위한 오베피탄트
TW202313050A (zh) 組合療法
JP2013515766A (ja) イマチニブジクロロ酢酸塩及びそれを含む抗癌剤組成物
JP7591283B2 (ja) ブドウ膜黒色腫の治療のための併用療法
KR102685187B1 (ko) Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도
HK1226732A1 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
HK1226732B (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
HK1205119B (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
JP7677646B2 (ja) 複製タンパク質ａ（ｒｐａ）－ｄｎａ相互作用阻害剤
HK1226300B (en) Fused bicyclic 2, 4-diaminopyrimidine derivative as a dual alk and fak inhibitor
WO2026012504A1 (zh) 用于降解目标蛋白的crbn结合化合物及其应用
JP2023526235A (ja) 骨髄性細胞白血病－１（ｍｃｌ－１）タンパク質の阻害剤としてのスピロ－スルホンアミド誘導体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)